NSAID Single-Drug-Induced Reactions

Immunology and Allergy Clinics of North America

Volumn 33, Issue 2, 2013, Pages 237-249

  Woessner, Katharine M ^a   Castells, Mariana ^b  

^a SCRIPPS CLINIC   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Acute generalized erythematous pustulosis (AGEP); Adverse drug reactions (ADRs); Drug rash with eosinophilia and systemic symptoms (DRESS); Nonsteroidal anti inflammatory drugs (NSAIDs); Stevens Johnson syndrome (SJS); Toxic epidermal necrolysis (TEN)

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; FENOPROFEN; FLURBIPROFEN; IBUPROFEN; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; INDOMETACIN; KETOPROFEN; KETOROLAC; MECLOFENAMATE SODIUM; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OXICAM DERIVATIVE; PARACETAMOL; PHENYLBUTAZONE; PIROXICAM; PROPIONIC ACID DERIVATIVE; ROFECOXIB; SULINDAC; TIAPROFENIC ACID; TOLMETIN; VALDECOXIB; ZOMEPIRAC;

ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; ALLERGIC PNEUMONITIS; ANAPHYLACTIC SHOCK; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTHRALGIA; ASEPTIC MENINGITIS; ASTHMA; BRONCHOSPASM; CARDIOTOXICITY; CEREBROVASCULAR ACCIDENT; CONTACT DERMATITIS; CROSS REACTION; DIAGNOSTIC ACCURACY; DIARRHEA; DRESS SYNDROME; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FIXED DRUG ERUPTION; HEART INFARCTION; HUMAN; IMMUNE RESPONSE; INCIDENCE; LARYNX EDEMA; MACULOPAPULAR RASH; MALAISE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PATCH TEST; PATHOPHYSIOLOGY; PHOTOALLERGY; PNEUMONIA; PRIORITY JOURNAL; PROVOCATION TEST; PRURITUS; REVIEW; RHINITIS; SKIN TEST; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; URTICARIA; VOMITING;

ANAPHYLAXIS; ANGIOEDEMA; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DRUG HYPERSENSITIVITY; HUMANS; HYPERSENSITIVITY, DELAYED; URTICARIA;

EID: 84877085161     PISSN: 08898561     EISSN: 15578607     Source Type: Journal    
DOI: 10.1016/j.iac.2012.12.002     Document Type: Review

References (83)

1. Gomes E.R., Demoly P. Epidemiology of hypersensitivity drug reactions. Curr Opin Allergy Clin Immunol 2005, 5:309-316.
2. Nettis E., Colanardi M.C., Ferrannini A., et al. Update on sensitivity to nonsteroidal antiinflammatory drugs. Curr Drug Targets Immune Endocr Metabol Disord 2001, 1:233-240.
3. Settipane R.A., Constantine H.P., Settipane G.A. Aspirin intolerance and recurrent urticaria in normal adults and children. Epidemiology and review. Allergy 1980, 35:149-154.
4. Khan D.A., Solensky R. Drug allergy. J Allergy Clin Immunol 2010, 125:S126-S137.
5. van Puijenbroek E.P., Egberts A.C., Meyboom R.H., et al. Different risks for NSAID-induced anaphylaxis. Ann Pharmacother 2002, 36:24-29.
6. Quiralte J., Blanco C., Delgado J., et al. Challenge-based clinical patterns of 223 Spanish patients with nonsteroidal anti-inflammatory-drug-induced-reactions. J Investig Allergol Clin Immunol 2007, 17:182-188.
7. Van der Klauw M.M., Wilson J.H., Stricker B.H. Drug-associated anaphylaxis: 20 years of reporting in The Netherlands (1974-1994) and review of the literature. Clin Exp Allergy 1996, 26:1355-1363.
8. Szczeklik A. Analgesics, allergy and asthma. Drugs 1986, 32(Suppl 4):148-163.
9. Gomez E., Blanca-Lopez N., Torres M.J., et al. Immunoglobulin E-mediated immediate allergic reactions to dipyrone: value of basophil activation test in the identification of patients. Clin Exp Allergy 2009, 39:1217-1224.
10. Layton D., Marshall V., Boshier A., et al. Serious skin reactions and selective COX-2 inhibitors: a case series from prescription-event monitoring in England. Drug Saf 2006, 29:687-696.
11. Mockenhaupt M., Kelly J.P., Kaufman D., et al. The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: a multinational perspective. J Rheumatol 2003, 30:2234-2240.
12. Escribano L., Akin C., Castells M., et al. Mastocytosis: current concepts in diagnosis and treatment. Ann Hematol 2002, 81:677-690.
13. Stevenson D.D. Aspirin and NSAID sensitivity. Immunol Allergy Clin North Am 2004, 24:491-505.
14. Czerniawska-Mysik G., Szczeklik A. Idiosyncrasy to pyrazolone drugs. Allergy 1981, 36:381-384.
15. Blanca M., Perez E., Garcia J.J., et al. Angioedema and IgE antibodies to aspirin: a case report. Ann Allergy 1989, 62:295-298.
16. Schwartz L.B., Metcalfe D.D., Miller J.S., et al. Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N Engl J Med 1987, 316:1622-1626.
17. Asero R. Oral aspirin challenges in patients with a history of intolerance to single non-steroidal anti-inflammatory drugs. Clin Exp Allergy 2005, 35:713-716.
18. Sanchez-Borges M. NSAID hypersensitivity (respiratory, cutaneous, and generalized anaphylactic symptoms). Med Clin North Am 2010, 94:853-864.
19. de Paramo B.J., Gancedo S.Q., Cuevas M., et al. Paracetamol (acetaminophen) hypersensitivity. Ann Allergy Asthma Immunol 2000, 85:508-511.
20. Liao C.M., Chen W.C., Lin C.Y. Study of an anaphylactoid reaction to acetaminophen. Acta Paediatr Taiwan 2002, 43:147-152.
21. Harrer A., Lang R., Grims R., et al. Diclofenac hypersensitivity: antibody responses to the parent drug and relevant metabolites. PLoS One 2010, 5:e13707.
22. Viola M., Rumi G., Valluzzi R.L., et al. Assessing potential determinants of positive provocation tests in subjects with NSAID hypersensitivity. Clin Exp Allergy 2011, 41:96-103.
23. Kemp S.F., Lockey R.F., Wolf B.L., et al. Anaphylaxis. A review of 266 cases. Arch Intern Med 1995, 155:1749-1754.
24. Phills J.A., Perelmutter L. IgE mediated and non-IgE mediated allergic-type reactions to aspirin. Acta Allergol 1974, 29:474-490.
25. Svensson C.K., Cowen E.W., Gaspari A.A. Cutaneous drug reactions. Pharmacol Rev 2001, 53:357-379.
26. Roujeau J.C., Stern R.S. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994, 331:1272-1285.
27. Savin J.A. Current causes of fixed drug eruption in the UK. Br J Dermatol 2001, 145:667-668.
28. Mahboob A., Haroon T.S. Drugs causing fixed eruptions: a study of 450 cases. Int J Dermatol 1998, 37:833-838.
29. Yesudian P.D., Penny M., Azurdia R.M., et al. Ibuprofen-induced acute generalized exanthematous pustulosis. Int J Dermatol 2004, 43:208-210.
30. Teixeira M., Silva E., Selores M. Acute generalized exanthematous pustulosis induced by nimesulide. Dermatol Online J 2006, 12:20.
31. Pakdeethai J., Ho S.A., Aw D., et al. Acute generalized exanthematous pustulosis-like, folliculitic drug reaction pattern caused by celecoxib. Dermatol Ther 2011, 24:505-507.
32. Ghislain P.D., De Beir A., Creusy C., et al. Keratosis lichenoides chronica: report of a new case, with success of PUVA therapy. Dermatol Online J 2001, 7:4.
33. Mockenhaupt M., Viboud C., Dunant A., et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008, 128:35-44.
34. Kim H.I., Kim S.W., Park G.Y., et al. Causes and treatment outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in 82 adult patients. Korean J Intern Med 2012, 27:203-210.
35. Kaufman D.W., Kelly J.P. Acetylsalicylic acid and other salicylates in relation to Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Clin Pharmacol 2001, 51:174-176.
36. Kelemen J.J., Cioffi W.G., McManus W.F., et al. Burn center care for patients with toxic epidermal necrolysis. J Am Coll Surg 1995, 180:273-278.
37. Cheriyan S., Patterson R., Greenberger P.A., et al. The outcome of Stevens-Johnson syndrome treated with corticosteroids. Allergy Proc 1995, 16:151-155.
38. Fine J.D. Management of acquired bullous skin diseases. N Engl J Med 1995, 333:1475-1484.
39. Becker D.S. Toxic epidermal necrolysis. Lancet 1998, 351:1417-1420.
40. Viard I., Wehrli P., Bullani R., et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998, 282:490-493.
41. Prins C., Kerdel F.A., Padilla R.S., et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003, 139:26-32.
42. Trent J.T., Kerdel F.A. Intravenous immunoglobulin for the treatment of toxic epidermal necrolysis. Arch Dermatol 2003, 139:1081.
43. Trent J.T., Kirsner R.S., Romanelli P., et al. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: the University of Miami experience. Arch Dermatol 2003, 139:39-43.
44. Bachot N., Revuz J., Roujeau J.C. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 2003, 139:33-36.
45. Shortt R., Gomez M., Mittman N., et al. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil 2004, 25:246-255.
46. Paul C., Wolkenstein P., Adle H., et al. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol 1996, 134:710-714.
47. Hunger R.E., Hunziker T., Buettiker U., et al. Rapid resolution of toxic epidermal necrolysis with anti-TNF-alpha treatment. J Allergy Clin Immunol 2005, 116:923-924.
48. Fischer M., Fiedler E., Marsch W.C., et al. Antitumour necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis. Br J Dermatol 2002, 146:707-709.
49. Bocquet H., Bagot M., Roujeau J.C. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg 1996, 15:250-257.
50. Um S.J., Lee S.K., Kim Y.H., et al. Clinical features of drug-induced hypersensitivity syndrome in 38 patients. J Investig Allergol Clin Immunol 2010, 20:556-562.
51. Lee J.H., Park H.K., Heo J., et al. Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome induced by celecoxib and anti-tuberculosis drugs. J Korean Med Sci 2008, 23:521-525.
52. Kawakami T., Fujita A., Takeuchi S., et al. Drug-induced hypersensitivity syndrome: drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome induced by aspirin treatment of Kawasaki disease. J Am Acad Dermatol 2009, 60:146-149.
53. Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology, et al. Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol 2010, 105:259-273.
54. Fields K.S., Petersen M.J., Chiao E., et al. Case reports: treatment of nevirapine-associated dress syndrome with intravenous immune globulin (IVIG). J Drugs Dermatol 2005, 4:510-513.
55. Allen J.N. Drug-induced eosinophilic lung disease. Clin Chest Med 2004, 25:77-88.
56. Weber J.C., Essigman W.K. Pulmonary alveolitis and NSAIDs-fact or fiction?. Br J Rheumatol 1986, 25:5-6.
57. Goodwin S.D., Glenny R.W. Nonsteroidal anti-inflammatory drug-associated pulmonary infiltrates with eosinophilia. Review of the literature and Food and Drug Administration Adverse Drug Reaction reports. Arch Intern Med 1992, 152:1521-1524.
58. Jolles S., Sewell W.A., Leighton C. Drug-induced aseptic meningitis: diagnosis and management. Drug Saf 2000, 22:215-226.
59. Moris G., Garcia-Monco J.C. The challenge of drug-induced aseptic meningitis. Arch Intern Med 1999, 159:1185-1194.
60. Moreno-Ancillo A., Gil-Adrados A.C., Jurado-Palomo J. Ibuprofen-induced aseptic meningoencephalitis confirmed by drug challenge. J Investig Allergol Clin Immunol 2011, 21:484-487.
61. Ashwath M.L., Katner H.P. Recurrent aseptic meningitis due to different non-steroidal anti-inflammatory drugs including rofecoxib. Postgrad Med J 2003, 79:295-296.
62. Ballas Z.K., Donta S.T. Sulindac-induced aseptic meningitis. Arch Intern Med 1982, 142:165-166.
63. Kowalski M.L., Makowska J.S., Blanca M., et al. Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) - classification diagnosis and management: review of the EAACI/ENDA(#) and GA2LEN/HANNA*. Allergy 2011, 66:818-829.
64. Pigatto P.D., Mozzanica N., Bigardi A.S., et al. Topical NSAID allergic contact dermatitis. Italian experience. Contact Derm 1993, 29:39-41.
65. Gould J.W., Mercurio M.G., Elmets C.A. Cutaneous photosensitivity diseases induced by exogenous agents. J Am Acad Dermatol 1995, 33:551-573.
66. Bagheri H., Lhiaubet V., Montastruc J.L., et al. Photosensitivity to ketoprofen: mechanisms and pharmacoepidemiological data. Drug Saf 2000, 22:339-349.
67. Thyssen J.P., Maibach H.I. Drug-elicited systemic allergic (contact) dermatitis-update and possible pathomechanisms. Contact Derm 2008, 59:195-202.
68. Posadas S.J., Pichler W.J. Delayed drug hypersensitivity reactions-new concepts. Clin Exp Allergy 2007, 37:989-999.
69. Lakshmi C., Srinivas C.R. Systemic (allergic) contact dermatitis to diclofenac. Indian J Dermatol Venereol Leprol 2011, 77:536-540.
70. Jaeger C., Jappe U. Valdecoxib-induced systemic contact dermatitis confirmed by positive patch test. Contact Derm 2005, 52:47-48.
71. Barbaud A. Skin testing in delayed reactions to drugs. Immunol Allergy Clin North Am 2009, 29:517-535.
72. Shiohara T. Fixed drug eruption: pathogenesis and diagnostic tests. Curr Opin Allergy Clin Immunol 2009, 9:316-321.
73. Hasan T., Jansen C.T. Photopatch test reactivity: effect of photoallergen concentration and UVA dosaging. Contact Derm 1996, 34:383-386.
74. Aberer W., Bircher A., Romano A., et al. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy 2003, 58:854-863.
75. Bombardier C., Laine L., Reicin A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000, 343:1520-1528.
76. Juni P., Nartey L., Reichenbach S., et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004, 364:2021-2029.
77. Graham D.J., Campen D., Hui R., et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005, 365:475-481.
78. Bresalier R.S., Sandler R.S., Quan H., et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005, 352:1092-1102.
79. Solomon S.D., McMurray J.J., Pfeffer M.A., et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005, 352:1071-1080.
80. Ray W.A., Stein C.M., Daugherty J.R., et al. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002, 360:1071-1073.
81. Solomon D.H., Schneeweiss S., Glynn R.J., et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004, 109:2068-2073.
82. Mamdani M., Juurlink D.N., Lee D.S., et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004, 363:1751-1756.
83. Mason R.P., Walter M.F., Day C.A., et al. A biological rationale for the cardiotoxic effects of rofecoxib: comparative analysis with other COX-2 selective agents and NSAids. Subcell Biochem 2007, 42:175-190.